Maxalt Tablet
Product Images NDC 78206-142

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Maxalt (NDC 78206-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Organon Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Rizatriptan Benzoate Chemical Structure (Maxalt 01)

Chemical structure of rizatriptan benzoate, the active ingredient in MAXALT-MLT 10 mg orally disintegrating tablets. The diagram shows the molecular arrangement of rizatriptan connected to a benzoate group.*

FDA Label Image

Image Of Figure 1 (Maxalt 02)

A line graph depicting the estimated probability of response over 2 hours post-dose, comparing placebo, MAXALT 5 mg, and MAXALT 10 mg. The graph shows increasing response rates over time, with MAXALT 10 mg having the highest response, followed by MAXALT 5 mg, and placebo the lowest.*

FDA Label Image

Image Of Figure 2 (Maxalt 03)

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose. Three curves represent Placebo, MAXALT 5 mg, and MAXALT 10 mg, with Placebo showing the highest probability, followed by MAXALT 5 mg, and MAXALT 10 mg the lowest among the three over time.*

FDA Label Image

Image Of Figure 3 (Maxalt 04)

A line graph showing the estimated probability of response over time post-dose for MAXALT-MLT 5 mg, MAXALT-MLT 10 mg, and placebo. The x-axis represents hours post-dose from 0 to 2, and the y-axis shows the estimated probability of response from 0% to 100%. Both strengths of MAXALT-MLT exhibit higher response probabilities than placebo, increasing over time up to 2 hours.*

FDA Label Image

Image Of Figure 4 (Maxalt 05)

A line graph depicting the estimated probability of medication or rescue over 24 hours post-dose. It compares three treatments: placebo, MAXALT-MLT 5 mg, and MAXALT-MLT 10 mg, showing the probability on the Y-axis and hours post-dose on the X-axis. The placebo line shows the highest probability over time, while MAXALT-MLT 10 mg shows the lowest.*

FDA Label Image

Image Of Figure 5 (Maxalt 06)

A line graph comparing percentage outcomes with 95% confidence intervals for MAXALT-MLT and placebo over time, measured in hours post stage 2 dose. The graph shows data points at 0.5, 1, 1.5, and 2 hours, with MAXALT-MLT represented by a solid line and placebo by a dashed line, indicating increasing percentages over time for both treatments.*

FDA Label Image

Principal Display Panel (10 mg Tablet Pouch Carton)

Packaging label for MAXALT-MLT 10 mg orally disintegrating tablets containing rizatriptan benzoate. The blue and white carton contains 18 tablets and is labeled with the NDC 78206-142-01. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd., distributed by Organon LLC. The label includes directions to apply the pharmacy label and storage instructions.*

FDA Label Image

Principal Display Panel (10 mg Tablet Case Carton)

Packaging label for MAXALT-MLT 10 mg orally disintegrating tablets (rizatriptan benzoate) by Organon LLC. The label indicates each carrying case contains 3 orally disintegrating tablets and 6 carrying cases per package. Storage instructions note room temperature (59-86°F). The label includes a barcode and mentions phenylalanine content for phenylketonurics.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.